Sunshine Biopharma Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 7, 2022 and accepted by EDGAR at Nov 7, 2022, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $132.8k | us-gaap:Revenues |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $405.8k | us-gaap:Revenues |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $65.8k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $200.3k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $67.0k | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $205.4k | us-gaap:GrossProfit |
| Research and development | 3 months2022-07-01 to 2022-09-30 | $362.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $770.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$3.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $2 | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $12.9k | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$1.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$3.2m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$3.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-09-30 | $40.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $40.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $40.9m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $480.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $480.2k | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $40.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-22-007290. Last ingested by Listed: Nov 11, 2026, 03:50 ET. Listed shows no prices and gives no investment advice.